LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to extend the cash runway further into 2026 UTRECHT, The …